...
首页> 外文期刊>AIDS Research and Human Retroviruses >Determination of the high prevalence of Dual/Mixed- or X4-tropism among HIV type 1 CRF01-AE in Hong Kong by genotyping and phenotyping methods
【24h】

Determination of the high prevalence of Dual/Mixed- or X4-tropism among HIV type 1 CRF01-AE in Hong Kong by genotyping and phenotyping methods

机译:用基因分型和表型分析方法确定香港HIV 1型CRF01-AE中双重/混合或X4-趋向性的高患病率

获取原文
获取原文并翻译 | 示例
           

摘要

In Hong Kong, the CCR5 antagonist has recently been introduced into salvage therapy for multiclass drug-resistant HIV-1-infected patients. Coreceptor usage must be determined prior to the usage of the CCR5 antagonist, which does not inhibit X4-tropic viruses. This study aimed to determine the tropism prevalence for HIV-1 subtypes B and CRF01-AE in Hong Kong. In addition, a modified promoter-PCR phenotypic assay was used to validate the genotypic tropism prediction on CRF01-AE. One hundred and five subtype B and 98 CRF01-AE antiretroviral-naive patients were recruited for this study. The viral env V3 region isolated from the patients was sequenced and analyzed by Geno2pheno (FPR=5.75% or 10%, Clonal or Clinical), position-specific scoring matrix (WebPSSM, x4r5 subtype B matrix), and the combination of 11/25 and net charge rules. Fifteen concordant and 22 discordant tropism genotyped CRF01-AE samples were further phenotyped by either enhanced sensitivity Trofile assay or an optimized promoter-PCR phenotypic assay. The prevalence of Dual/Mixed- or X4-tropic virus in antiretroviral-naive subtype CRF01-AE was 39.1%, which was significantly higher than subtype B (p<0.05), regardless of the choices of genotypic algorithms. Our phenotypic data proposed that a better genotypic tropism prediction for HIV-1 CRF01-AE would be using both Geno2pheno (FPR=10%, Clonal) and WebPSSM (x4r5 subtype B matrix) algorithms in combination. The sensitivity and specificity for this combination were 88.9% and 89.3%, respectively. The comparatively high prevalence of Dual/Mixed- or X4-tropic virus in CRF01-AE demonstrated the need for special attention to future treatment strategies.
机译:在香港,CCR5拮抗剂最近已被引入挽救疗法中,用于治疗多类耐药HIV-1感染的患者。必须在使用不抑制X4-tropic病毒的CCR5拮抗剂之前确定共受体的使用。这项研究旨在确定香港HIV-1亚型B和CRF01-AE的嗜性流行情况。另外,使用改良的启动子-PCR表型测定法来验证CRF01-AE的基因型向性预测。招募了105位B型亚型和98位CRF01-AE初次使用抗逆转录病毒的患者。对从患者中分离出的病毒env V3区域进行测序,并通过Geno2pheno(FPR = 5.75%或10%,克隆或临床),位置特异性评分矩阵(WebPSSM,x4r5 B亚型矩阵)和11/25的组合进行分析和净费用规则。通过提高灵敏度的Trofile分析或优化的启动子-PCR表型分析,进一步对15个一致性和22个不一致的基因型CRF01-AE样品进行了表型分析。在初次使用抗逆转录病毒的CRF01-AE亚型中,Dual / Mixed或X4-tropic病毒的患病率为39.1%,无论是否选择基因型算法,其显着高于B亚型(p <0.05)。我们的表型数据表明,结合使用Geno2pheno(FPR = 10%,克隆)和WebPSSM(x4r5 B型亚型矩阵)算法,可以更好地预测HIV-1 CRF01-AE的基因型向性。该组合的敏感性和特异性分别为88.9%和89.3%。在CRF01-AE中,Dual / Mixed / X4-tropic病毒相对较高的流行率表明需要特别注意将来的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号